Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.
Diego Sánchez-MartínezNéstor TiradoSofia MensuradoAlba Martínez-MorenoPaola RomecínFrancisco Gutiérrez AgüeraDaniel V CorreiaBruno Silva-SantosPablo MenéndezPublished in: Journal for immunotherapy of cancer (2022)
Our results provide the proof-of-concept for a DOT-based next-generation allogeneic CAR-T therapy for AML.